FDA warns of liver damage reports with Sanofi drug

Jan 14, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health officials are warning doctors and patients that a recently-launched heart drug from Sanofi-Aventis SA has been linked to liver damage in a handful of patients.

The said Friday it has received several reports of with Multaq tablets, including two cases in which patients had to have their livers removed. Both patients were women and roughly 70 years old. They had been taking the drug for 4.5 months and 6 months, respectively.

The FDA approved Multaq in July 2009 to treat atrial flutter and which are that can reduce blood flow and lead to stroke. More than a half-million prescriptions for Multaq have been written since the drug was approved.

In an online notice, the FDA said it would add a new warning about the risk for liver damage to the label of Multaq. The agency said patients should contact their doctor if they experience signs of , including nausea, vomiting and fever. If doctors suspect a toxicity issue they should discontinue use of the drug and test the patient's liver enzymes.

Liver toxicity is among the most common drug-related side effects across a number of medication classes.

Multaq already carries a black box warning, the most severe type, stating the drug can cause severe complications, including death, in people with recent severe and should not be used in those patients. Common side effects of the twice-a-day tablets include fatigue, loss of strength, diarrhea, nausea and vomiting.

Paris-based Sanofi reported $84 million in sales for Multaq in the first-half of 2009.

Leerink Swann analyst Seamus Fernandez said the safety warning is unlikely to hurt U.S. sales of drug, which he estimates at $128 million for 2010 and $521 million by 2016.

Sanofi said in a statement it has already issued a letter about the liver injuries to doctors and other health care professionals who prescribe Multaq. The letter recommends prescribers consider giving liver enzyme tests during the first six months of treatment.

"Sanofi-Aventis will continue to be in communication with the FDA and this issue will be closely reviewed and monitored," the company stated.

Explore further: India's meth addiction grows as criminals tap chemical hub

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA warning: some patients cannot process Plavix

Mar 12, 2010

(AP) -- The Food and Drug Administration is adding its strongest warning to the label for Plavix, cautioning that some patients do not respond to the blockbuster blood thinner.

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0